BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24917033)

  • 1. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.
    Pearlstein MV; Zedek DC; Ollila DW; Treece A; Gulley ML; Groben PA; Thomas NE
    J Cutan Pathol; 2014 Sep; 41(9):724-32. PubMed ID: 24917033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
    Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra- and Inter-Tumor
    Ito T; Kaku-Ito Y; Murata M; Ichiki T; Kuma Y; Tanaka Y; Ide T; Ohno F; Wada-Ohno M; Yamada Y; Oda Y; Furue M
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
    Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
    Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
    Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
    Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
    BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
    Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
    Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
    Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
    Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
    Scolyer RA; Atkinson V; Gyorki DE; Lambie D; O'Toole S; Saw RPM; Amanuel B; Angel CM; Button-Sloan AE; Carlino MS; Ch'ng S; Colebatch AJ; Daneshvar D; Pires da Silva I; Dawson T; Ferguson PM; Foster-Smith E; Fox SB; Gill AJ; Gupta R; Henderson MA; Hong AM; Howle JR; Jackett LA; James C; Lee CS; Lochhead A; Loh D; McArthur GA; McLean CA; Menzies AM; Nieweg OE; O'Brien BH; Pennington TE; Potter AJ; Prakash S; Rawson RV; Read RL; Rtshiladze MA; Shannon KF; Smithers BM; Spillane AJ; Stretch JR; Thompson JF; Tucker P; Varey AHR; Vilain RE; Wood BA; Long GV
    Pathology; 2022 Feb; 54(1):6-19. PubMed ID: 34937664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
    Manfredi L; Meyer N; Tournier E; Grand D; Uro-Coste E; Rochaix P; Brousset P; Lamant L
    Acta Derm Venereol; 2016 Jun; 96(5):630-4. PubMed ID: 26695089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.